Page 128 - 中国全科医学2022-20

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·2557·

in type 2 diabetes［J］. Eur J Endocrinol，2022，186（2）：207- steatohepatitis and bridging fibrosis or compensated cirrhosis［J］.
221. DOI：10.1530/EJE-21-0865. Contemp Clin Trials，2021，104：106335. DOI：10.1016/j.
［54］BENNETT C F，SWAYZE E E. RNA targeting therapeutics： cct.2021.106335.
molecular mechanisms of antisense oligonucleotides as a therapeutic ［67］KIM A M，SOMAYAJI V R，DONG J Q，et al. Once-weekly
platform［J］. Annu Rev Pharmacol Toxicol，2010，50：259-293. administration of a long-acting fibroblast growth factor 21 analogue
DOI：10.1146/annurev.pharmtox.010909.105654. modulates lipids，bone turnover markers，blood pressure and body
［55］CROOKE S T，WITZTUM J L，BENNETT C F，et al. RNA- weight differently in obese people with hypertriglyceridaemia and in
targeted therapeutics［J］. Cell Metab，2019，29（2）：501. non-human Primates［J］. Diabetes Obes Metab，2017，19（12）：
DOI：10.1016/j.cmet.2019.01.001. 1762-1772. DOI：10.1111/dom.13023.
［56］MORGAN E S，TAI L J，PHAM N C，et al. Antisense inhibition ［68］TURNER T，CHEN X，ZAHNER M，et al. FGF21 increases water
of glucagon receptor by IONIS-GCGRRximproves type 2 diabetes intake，urine output and blood pressure in rats［J］. PLoS One，
without increase in hepatic glycogen content in patients with type 2 2018，13（8）：e0202182. DOI：10.1371/journal.pone.0202182.
diabetes on stable metformin therapy［J］. Diabetes Care，2019，42（4）： ［69］PAN D S，WANG W，LIU N S，et al. Chiglitazar preferentially
585-593. DOI：10.2337/dc18-1343. regulates gene expression via configuration-restricted binding and
［57］JOHNSON T O，ERMOLIEFF J，JIROUSEK M R. Protein tyrosine phosphorylation inhibition of PPARγ［J］. PPAR Res，2017，
phosphatase 1B inhibitors for diabetes［J］. NatRev Drug Discov， 2017：4313561. DOI：10.1155/2017/4313561.
2002，1（9）：696-709. DOI：10.1038/nrd895. ［70］DEEKS E D. Chiglitazar：first approval［J］. Drugs，2022，82（1）：
［58］DIGENIO A，PHAM N C，WATTS L M，et al. Antisense inhibition 87-92. DOI：10.1007/s40265-021-01648-1.
of protein tyrosine phosphatase 1B with IONIS-PTP-1B Rx improves ［71］LI X J，YU J，WU M，et al. Pharmacokinetics and safety of
insulin sensitivity and reduces weight in overweight patients with chiglitazar，a peroxisome proliferator-activated receptor pan-
type 2 diabetes［J］. Diabetes Care，2018，41（4）：807-814. agonist，in patients <65 and ≥ 65 years with type 2 diabetes［J］.
DOI：10.2337/dc17-2132. Clin Pharmacol Drug Dev，2021，10（7）：789-796. DOI：
［59］LUO J，HOU Y F，XIE M Y，et al. CYC31，A natural 10.1002/cpdd.893.
bromophenol PTP1B inhibitor，activates insulin signaling and ［72］LI R，METCALFE M J，FERGUSON J E 3rd，et al. Effects of
improves long chain-fatty acid oxidation in C2C12 myotubes［J］. thiazolidinedione in patients with active bladder cancer［J］. BJU
Mar Drugs，2020，18（5）：E267. DOI：10.3390/md18050267. Int，2018，121（2）：244-251. DOI：10.1111/bju.14009.
［60］BRUDER-NASCIMENTOT，BUTLER B R，HERRENDJ，et al. ［73］ROUSSEL R，HADJADJ S，PASQUET B，et al. Thiazolidinedione
Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin use is not associated with worse cardiovascular outcomes：a study in
neurons reduces neurogenic control of blood pressure and protects 28，332 high risk patients with diabetes in routine clinical practice：
mice from leptin- and sympatho-mediated hypertension［J］. brief title：Thiazolidinedione use and mortality［J］. Int J Cardiol，
Pharmacol Res，2015，102：235-244. DOI：10.1016/j. 2013，167（4）：1380-1384. DOI：10.1016/j.ijcard.2012.04.019.
phrs.2015.10.012. ［74］GOLTSMAN I，KHOURY E E，WINAVER J，et al. Does
［61］GUZMÁN-ÁVILA R，FLORES-MORALES V，PAOLI P，et al. Thiazolidinedione therapy exacerbate fluid retention in congestive
Ursolic acid derivatives as potential antidiabetic agents：in vitro，in heart failure? ［J］. Pharmacol Ther，2016，168：75-97. DOI：
vivo，and in silico studies［J］. Drug Dev Res，2018，79（2）： 10.1016/j.pharmthera.2016.09.007.
70-80. DOI：10.1002/ddr.21422. ［75］KU Y H，CHO B J，KIM M J，et al. Rosiglitazone increases
［62］LIN X L，LIU Y B，HU H J. Metabolic role of fibroblast growth endothelial cell migration and vascular permeability through Akt
factor 21 in liver，adipose and nervous system tissues［J］. Biomed phosphorylation［J］. BMC Pharmacol Toxicol，2017，18（1）：
Rep，2017，6（5）：495-502. DOI：10.3892/br.2017.890. 62. DOI：10.1186/s40360-017-0169-y.
［63］KHARITONENKOV A，SHIYANOVA T L，KOESTER A，et al. ［76］FAROOQUI K J，MITHAL A，KERWEN A K，et al. Type 2
FGF-21 as a novel metabolic regulator［J］. J Clin Invest，2005， diabetes and bone fragility—an under-recognized association［J］.
2
115（6）：1627-1635. DOI：10.1172/JCI 3606. Diabetes Metab Syndr，2021，15（3）：927-935. DOI：
［64］KHARITONENKOV A，ADAMS A C. Inventing new medicines： 10.1016/j.dsx.2021.04.017.
the FGF21 story［J］. Mol Metab，2014，3（3）：221-229. ［77］DEPAOLI A M，HIGGINS L S，HENRY R R，et al. Can a selective
DOI：10.1016/j.molmet.2013.12.003. PPARγ modulator improve glycemic control in patients with type 2
［65］GAICH G，CHIEN J Y，FU H D，et al. The effects of diabetes with fewer side effects compared with pioglitazone? ［J］.
LY2405319，an FGF21 analog，in obese human subjects with type Diabetes Care，2014，37（7）：1918-1923. DOI：10.2337/
2 diabetes［J］. Cell Metab，2013，18（3）：333-340. DOI： dc13-2480.
10.1016/j.cmet.2013.08.005. ［78］DEFRONZO R A. Lilly lecture 1987. The triumvirate：beta-cell，
［66］ABDELMALEK M F，CHARLES E D，SANYAL A J，et al. muscle，liver. A collusion responsible for NIDDM［J］. Diabetes，
The FALCON program：two phase 2b randomized，double- 1988，37（6）：667-687. DOI：10.2337/diab.37.6.667.
blind，placebo-controlled studies to assess the efficacy and safety （收稿日期：2022-01-08；修回日期：2022-03-07）
of pegbelfermin in the treatment of patients with nonalcoholic （本文编辑：毛亚敏）